Summary Background Chronic hepatitis B (CHB) cannot be completely eradicated due to
the presence of covalently closed circular DNA (ccc DNA) in the nuclei of infected …

Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis
(RA), was first approved for treatment of RA in Japan in 1999 at the recommended dose of 6 …

Aim To update recommendations based on current best evidence concerning the treatment
of rheumatoid arthritis (RA), focusing particularly on the role of targeted therapies, to inform …

Background There remains an unmet need for convenient biomarkers to assess the risks of
discontinuing nucleos (t) ide analogues (NAs) in chronic hepatitis B (CHB). Aim To …

The correlation between serum HB crAg and HBV RNA is unclear, and correlations of
intrahepatic ccc DNA with HB crAg, HBV RNA and HB sAg are rarely reported in the same …

Background Safe nucleos (t) ide analogue discontinuation in chronic hepatitis B (CHB) is an
unmet need. We aimed to investigate whether combining hepatitis B virus (HBV) RNA and …

Background Chronic hepatitis B virus (HBV) infection is an aetiologic factor for
hepatocellular carcinoma (HCC). Baseline HBV DNA is a known independent predictor of …

Direct‐acting antiviral agents (DAA) for hepatitis C virus (HCV) are not effective for hepatitis
B virus (HBV), which may be suggestive of reactivation of anti‐HBe hepatitis during …

Background Entecavir and tenofovir–disoproxil–fumarate are first-line nucleos (t) ide
analogs (NA) for treatment of hepatitis B virus (HBV) infections; however, their long-term …

Background Although the reactivation of hepatitis B virus (HBV) is recognised as a serious
complication in patients with rheumatic disease (RD) receiving immunosuppressive drugs …